Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Current Assets (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Current Assets for 16 consecutive years, with $17.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 227.85% to $17.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.6 million, a 227.85% increase, with the full-year FY2024 number at $5.3 million, down 46.52% from a year prior.
  • Current Assets was $17.6 million for Q3 2025 at Plus Therapeutics, up from $9.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $22.1 million in Q1 2022 to a low of $4.2 million in Q1 2024.
  • A 5-year average of $13.8 million and a median of $13.0 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: tumbled 69.09% in 2024, then surged 227.85% in 2025.
  • Plus Therapeutics' Current Assets stood at $22.1 million in 2021, then fell by 1.27% to $21.8 million in 2022, then crashed by 54.93% to $9.8 million in 2023, then tumbled by 46.52% to $5.3 million in 2024, then surged by 234.4% to $17.6 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Current Assets are $17.6 million (Q3 2025), $9.2 million (Q2 2025), and $10.9 million (Q1 2025).